ReviewCancer immunology, immunotherapy : CII2018
Cancer immunotherapy in patients with brain metastases.
Review in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.Nature communications · 2021Trial
- Host's immune response to primary tumours and concomitant brain metastases in the central nervous system.Contemporary oncology (Poznan, Poland) · 2026Article
- Immune architecture of colorectal cancer brain metastases: spatial TAM heterogeneity and PD-L1 dynamics.Frontiers in immunology · 2026Article
- Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study.Frontiers in immunology · 2024Article
- Article
- Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis.Nature cancer · 2021Article
- Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis.Molecules (Basel, Switzerland) · 2020Article
- Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status.Journal for immunotherapy of cancer · 2020Article
- Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients.Journal of the National Cancer Institute · 2020Review
- Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade.Neuro-oncology practice · 2019Article
- Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases.International journal of molecular sciences · 2019Review
- Advanced Magnetic Resonance Imaging Techniques in Management of Brain Metastases.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The exclusion of "real-world" patients from registration clinical trials of cancer immunotherapy represents a significant emerging issue. For instance, a large fraction of cancer patients develops brain metastases during the course of the disease, but results from large prospective clinical trials investigating this considerable proportion of the cancer patient population are currently lacking. To provide a useful tool for the clinician in a "real-world" setting, we have reviewed the available literature regarding the safety and efficacy of immune check-point inhibitors in patients with cancer metastatic to the brain. Overall, these data provide encouraging evidence that these therapeutic agents can induce intracranial objective responses, particularly in patients with asymptomatic and previously untreated brain metastases. Larger prospective studies are needed to confirm these initial results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.